Streetbeat News

PTPI

Petros Pharmaceuticals, Inc.

https://www.petrospharma.com

Industry

Drug Manufacturers - Specialty & Generic

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Open

0.26

Mkt cap

2.7M

Volume

396K

High

0.28

P/E Ratio

-0.07

52-wk high

2.27

Low

0.25

Div yield

N/A

52-wk low

0.22

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Notable gainers include SINTX Techs (SINT), Petros Pharma (PTPI), and Bluejay Diagnostics (BJDX). Significant losers include Eyenovia (EYEN), Lucy Scientific Discovery (LSDI), and Monte Rosa Therapeutics (GLUE).

Portfolio Pulse from Benzinga Insights

May 15, 2024 | 8:32 pm

Petros Pharmaceuticals has announced the launch of U.S. distribution for its erectile dysfunction medication, STENDRA, through a collaboration with 23andMe's subsidiary, Lemonaid Health. This partnership aims to provide customers with more affordable access to STENDRA, which can be taken shortly before sexual activity.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 1:23 pm

Petros Pharmaceuticals Inc has filed for a mixed shelf offering of up to $100 million, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 10:44 pm

Petros Pharmaceuticals has announced an expansion of its online distribution for the prescription medication STENDRA through a new agreement with Lemonaid Health. This collaboration aims to enhance the marketing and distribution of STENDRA for erectile dysfunction (ED) patients using Lemonaid Health's telemedicine services.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:20 pm

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) received positive feedback from the FDA on its technology component for STENDRA's self-selection, aiming for OTC status. This feedback is a crucial step towards making STENDRA the first erectile dysfunction drug available OTC. The FDA's informal review acknowledged the technology's potential to address concerns related to the PDE5 inhibitor class, especially for nitrate-using patients. Petros plans to submit its pivotal two-arm Self-Selection study in 2H 2024, with further guidance on an upcoming Application Comprehension Study.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 1:18 pm

Stryve Foods shares plummeted by 25% due to a significant fourth-quarter revenue miss. Other stocks experienced notable movements, with VivoPower International surging 315% after announcing a merger, and Acorda Therapeutics dropping 83.5% following a Chapter 11 bankruptcy filing. Various companies reported financial results, mergers, and other significant updates affecting their stock prices.

Portfolio Pulse from Avi Kapoor

April 02, 2024 | 5:23 pm

Petros Pharmaceuticals' shares declined following the announcement of disappointing Q4 earnings per share (EPS) results, falling short of market expectations.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 3:42 pm

Petros Pharmaceuticals reported a Q4 EPS of $(2.17), missing the $(1.11) estimate by 95.5%, and sales of $364.25K, missing the $1.55M estimate by 76.5%. This represents a decrease in performance compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:12 pm

In Tuesday's pre-market session, health care stocks showed significant movement. MSP Recovery, Serina Therapeutics, and CareMax were among the top gainers, with MSP Recovery leading at a 61.9% increase. On the downside, Acorda Therapeutics experienced a sharp decline of 75.1%, followed by Gritstone Bio and Verve Therapeutics. Notably, several companies released their Q4 earnings reports, influencing stock movements.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 12:07 pm

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) has announced the successful launch of an AI tool developed in collaboration with a major software provider, aimed at optimizing self-screening for STENDRA (avanafil), an erectile dysfunction medication in development for OTC status. The AI tool is part of a Human Factors study designed to assess the safety and effectiveness of the web app used for patient self-screening, in line with FDA guidance. The company believes this AI integration will address FDA requests and help achieve significant clinical milestones for STENDRA.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 1:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.